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Paraquat (PQ) poisoning causes severe lung injury. PQ-induced pulmonary inﬂammation and ﬁbrosis are due
to its ability to induce oxidative stress, inﬂammatory and ﬁbrotic reactions. This study was designed to eval-
uate the anti-inﬂammatory and anti-ﬁbrotic effect of thalidomide on PQ-induced lung damage in a mouse
model. Mice were injected with a single dose of PQ (20 mg/kg, i.p.), and treated with thalidomide (25 and
50 mg/kg/day, i.p.) for six days. Lung tissues were dissected six days after PQ injection. The results showed
that thalidomide ameliorated the biochemical and histological lung alterations induced by PQ. Thalidomide
decreased production of inﬂammatory and ﬁbrogenic cytokine tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, IL-6, and transforming growth factor (TGF)-β1. In addition thalidomide reduced myeloperoxidase
(MPO), nitric oxide (NO), and hydroxyproline content in lung tissue. Taken together, the results of this
study suggest that thalidomide might be a valuable therapeutic drug in preventing the progression of
PQ-induced pulmonary injury.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Paraquat (1,1′-dimethyl-4,4′-bipyridinium chloride) is a widely
used herbicide that can cause severe lung injury in humans. Exposure
to PQ leads to accumulation of PQ in the lungs resulting in pulmonary
edema, alveolar destruction, proliferation of bronchial epithelial cells
and eventually ﬁbrosis. Pulmonary ﬁbrosis is a major hallmark and a
leading cause of death in PQ poisoning [1,2].
Paraquat redox cycling and subsequent generation of reactive oxy-
gen species (ROS), hydroxyl free radical (HO•) and peroxynitrite
(ONOO−) is the primary mechanism for initiating lung damage by PQ.
These mediators induce intracellular transcription factors and then
many proinﬂammatory agents including inducible nitric oxide synthase
(iNOS), inﬂammatory cytokines, and cyclooxygenase (COX) all of which
exaggerate the inﬂammatory process [3,4]. From themolecular aspects,
nitric oxide (NO) and proinﬂammatory cytokines, particularly TNF-α,
IL-6, IL-1β, and TGF-β1 may be the core of the pathogenesis of
PQ-induced lung injury and ﬁbrosis [4–6]. Although there is no effective
therapy for PQ poisoning, anti-inﬂammatory drugs have been used in
the clinical treatment of PQ-poisoned patients [7,8]. Generally, cortico-
steroids and immunosuppressive drugs are the mainstay of treatment
for PQ-induced lung injury.
As mentioned above, it may be hypothesized that an effective
treatment against PQ-induced lung injury and ﬁbrosis should have
considerable anti-inﬂammatory and anti-ﬁbrotic effects. It has been10052; fax: +98 451 5510057.
rshahrokhi@gmail.com.
rights reserved.reported that thalidomide as an anti-inﬂammatory agent is effective
in the prevention of pulmonary inﬂammation and ﬁbrosis in the exper-
imental models [9–11]. Thalidomide (α-N-phthalimido glutarimide) is
a glutamic acid derivative that was initially introduced as a sedative
drug but was withdrawn from the market for its teratogenic effects.
Thalidomide has various pharmacological properties, including
immunomodulation, anti-inﬂammation and anti-angiogenesis. Clinical
and experimental studies have demonstrated the efﬁcacy of thalido-
mide or its analogs in the treatment of a variety of disorders including
erythema nodosum leprosum, multiple myeloma, rheumatoid arthritis,
Crohn's disease, prostate cancer and lupus erythematosus [12]. It has
also been shown that thalidomide exhibits anti-inﬂammatory and
anti-ﬁbrotic activity by suppressing the production of proinﬂammatory
cytokines, growth factors and nitric oxide which play an important role
in the tissue destruction and ﬁbrosis in chronic inﬂammatory situations
[11,13–15].
In the present study, we examined whether thalidomide had pro-
tective effects on PQ-induced lung injury in mice. Furthermore, we
investigated the mechanism underlying the therapeutic effect of tha-
lidomide on pulmonary inﬂammation and ﬁbrosis.
2. Material and methods
2.1. Animal and chemicals
Male Swiss albino mice, weighing 25–30 g, were housed in a room
with a 12-h light/dark cycle. Animals were allowed free access to tap
water and ad libitum food. All animal procedures were performed in
Fig. 1. Effect of thalidomide on PQ-induced production of TNF-α (A), IL-1β (B), IL-6 (C) and TGF-β1(D) in mouse lung tissues. Thalidomide treatment (50 mg/kg/day, i.p.) signiﬁcantly
reduced PQ-induced production of proinﬂammatory cytokines TNF-α, IL-1β, IL-6 and TGF-β1. Data are means ± SD (two replicates in each assay), n = 8. *P b 0.001 compared with
normal group; §P b 0.001, #P b 0.05 compared with PQ group.
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(National Academies Press, Washington, DC, USA, 1996). Thalidomide,
tetramethylbenzidine, Tris–HCl buffer, dimethyl sulfoxide (DMSO),
hydrogen peroxide (H2O2), hydroxyproline, chloramine T and
p-dimethylaminobenzaldehyde were purchased from Sigma-Aldrich.
Paraquat was purchased from Afrashimi Co. (Iran).
2.2. Experimental design
The animals were randomly divided into ﬁve groups (8 mice in
each group), as follows: (1) Normal control group, mice received sa-
line solution. (2) Thal group, mice received Thal (50 mg/kg/day, ip).
(3) PQ group, mice received paraquat (20 mg/kg, i.p.). (4) PQ + Thal
25 group, mice received paraquat (20 mg/kg, i.p.) and thalidomide
(25 mg/kg/day, i.p.). (5) PQ + Thal 50 group, mice received paraquat
(20 mg/kg, i.p.) and thalidomide (50 mg/kg/day, i.p.). Paraquat was
dissolved in saline solution (NaCl 0.9%) and injected intraperitoneally
in a single toxic dose of 20 mg/kg of body weight. The dosage of PQ
was based on our preliminary experiments showing induction of
lung injury with lowest mortality. Thalidomide was dissolved in
0.5% carboxymethylcellulose and administered intraperitoneally for
six consecutive days.2.3. Tissue collection
At the end of the experiment, mice were anesthetized with keta-
mine and xylazine and their thoracic cavities were opened. One part
of the right lung was ﬁxed in formalin for histological examination,
and the remaining lung tissues were immediately removed and
washed in normal saline solution and frozen in liquid nitrogen.
2.4. Histological examination
Lung samples were ﬁxed with 10% formalin embedded in parafﬁn
and sections were stained with hematoxylin and eosin (H&E). The se-
verity of lung damage was scored using the criteria as follows. Score
0 = no injury. Score 1 = alveolar inﬂammation without thickening
of the alveolar septum. Score 2 = extensive alveolar inﬂammation
and thickening of the alveolar septum. Score 3 = destruction of the
alveolar spaces or extensive thickening of the airway/vessel wall [16].
2.5. Measurement of TNF-α, IL-1β, IL-6, and TGF-β1levels
The samples were homogenized in Tris–HCl buffer (pH = 7.4)
containing protease inhibitors (trypsin and other serine and cysteine
Fig. 2. Effect of thalidomide on PQ-induced production of nitrate/nitrite in mouse
lung tissues. Thalidomide treatment (50 mg/kg/day, i.p.) decreased the effect of PQ
on the levels of nitrate/nitrite as a marker of NO production. Data are means ± SD
(two replicates in each assay), n = 8. *P b 0.001 compared with normal group;
§P = 0.001 compared with PQ group.
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4 °C) in a refrigerated centrifuge for 20 min and the supernatant
was taken and frozen at −80 °C. Supernatant samples were thawed
and analyzed for murine cytokine TNF-α, IL-1β, IL-6, and
TGF-β1levels using mouse-speciﬁc ELISA kits (eBioscience). Cytokine
concentrations in the samples were expressed as pg cytokine/mg of
protein [13].
2.6. Determination of tissue NO levels
An aliquot of the supernatant was used to determine NO levels.
Tissue levels of nitrate and nitrite as a marker of total NO concentra-
tion were measured by a nitrate/nitrite colorimetric assay kit (Cay-
man Chemical Company).
2.7. Determination of myeloperoxidase (MPO) activity
MPO activity of lung tissues was determined by the method de-
scribed by Dinis-Oliveira et al. [7]. Brieﬂy, MPO content was measured
by mixing 50 μl of supernatant with 50 μl of tetramethylbenzidine
dissolved in dimethyl sulfoxide. MPO activity was started by addition
of 50 μl of hydrogen peroxide (H2O2) dissolved in phosphate buffer
(50 mM, pH 5.4). The rate of change in absorbancewasmeasured spec-
trophotometrically at 650 nm using a microplate reader. MPO activity
was deﬁned as the quantity of enzyme which decomposes 1 μl of
H2O2 per min at 25 °C. The results were expressed as mU MPO/mg of
protein.
2.8. Hydroxyproline (HP) assay
The HP content of the lung tissue was determined by the method
described by Murrell et al. [17]. Brieﬂy, 100 mg samples were hydro-
lyzed in 1 mL of 6 N HCl for 12 h at 120 °C. All samples were kept at
60 °C until the HCl was completely evaporated. After reconstitution in
1 mL H2O, the pH adjusted to 6–7 with NaOH. One hundred microli-
ters of the samples were added to a 96-well plate. Hydroxyproline ox-
idation was initiated by addition of 50 μl of chloramine T (0.05 M).
After shaking, the plate was incubated for 20 min at room tempera-
ture. To develop the color 50 μl of p-dimethylaminobenzaldehyde
solution (1 M) was added to each well and the plate was incubated
at 60 °C for 20 min. After cooling, the absorbance was read at550 nm using a spectrophotometer. The HP concentrations were cal-
culated using a standard curve of HP concentrations between 10 and
100 μg/ml.2.9. Statistical analysis
Data were expressed as mean ± SD. Statistical signiﬁcance was
evaluated by using analysis of variance (ANOVA) followed by Tukey's
test. P b 0.05 was considered signiﬁcant.3. Results
3.1. Effect of thalidomide on the levels of TNF-α, IL-1β, IL-6, and TGF-β1
in mouse lung tissues
To evaluate the effect of thalidomide on PQ-induced lung injury, we
measured the levels of important proinﬂammatory and proﬁbrotic
cytokines TNF-α, IL-1β, IL-6 and TGF-β1 in lung tissues (Fig. 1). Thalid-
omide was applied in two doses of 25 and 50 mg/kg. Administration of
PQ caused signiﬁcant elevation of tissue levels of TNF-α, IL-1β, IL-6 and
TGF-β1 as comparedwith those in the control group. Treatment of mice
with thalidomide signiﬁcantly reduced PQ-induced production of
TNF-α, IL-1β, IL-6 and TGF-β1 compared to the PQ group in a
dose-dependent manner. Although there was a signiﬁcant reduction
in the levels of TNF-α and IL-1β in the group treated with the lower
dose of thalidomide (25 mg/kg) (Fig. 1A and B), the same effect was
not found in the levels of IL-6 and TGF-β1 (Fig. 1C and D). These results
suggest that thalidomide at a dose of 50 mg/kg may be more effective
on PQ-induced inﬂammatory cytokine production.3.2. Effects of thalidomide and PQ on tissue NO levels
Wemeasured the lung tissue levels of nitrate/nitrite as an indicator
of NO generation. As shown in Fig. 2, lung tissue levels of nitrate/nitrite
were increased in PQ-treatedmice (P b 0.001). Treatment of mice with
thalidomide (50 mg/kg) signiﬁcantly decreased PQ-induced produc-
tion of nitrate/nitrite (P = 0.001).3.3. Effects of thalidomide and PQ on MPO activity
We measured MPO activity as a sensitive marker of neutrophil inﬁl-
tration or inﬂammation in lung tissue. Administration of PQ signiﬁcantly
increased level of MPO, a marker of neutrophil inﬁltration into the in-
ﬂamed lung tissue, in comparison to control group (P b 0.001) (Fig. 3).
Treatment with thalidomide (50 mg/kg) signiﬁcantly reduced elevated
MPO activity compared to that in the PQ group (P = 0.019).3.4. Histological studies
Histological examination of lung tissues from each study group was
performed to evaluate the severity of PQ-induced lung damage. PQ ad-
ministration inducedmarked interstitial edema, widespread inﬂamma-
tory cell inﬁltration in the alveolar space and septum, diffuse alveoli
collapse and thickening of the alveolar septum (Fig. 4A). Histopatholog-
ical changes inmice treatedwith PQ plus thalidomide (50 mg/kg)were
signiﬁcantly lower than those in the PQ group. Furthermore, as shown
in Fig. 4B, in PQ-treated mice, pathological score was signiﬁcantly
higher than that of the control group. Treatment with thalidomide sig-
niﬁcantly decreased the pathological score comparedwith the PQ group
(P b 0.05), indicating that thalidomide ameliorated PQ-induced lung
injury.
Fig. 3. Administration of thalidomide (50 mg/kg/day, i.p.) decreased MPO activity
induced by PQ (20 mg/kg, i.p.) in lung tissues. Data are means ± SD (two replicates
in each assay), n = 8. *P b 0.001 compared with normal group; §P b 0.05 compared
with PQ group.
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tissue
Hydroxyproline is the main component of collagen protein in the
body. We measured the hydroxyproline content as a marker of ﬁbro-
sis in the lung tissue. As shown in Fig. 5, the hydroxyproline content
in lung of the PQ-treated mice signiﬁcantly increased compared
with the control group. Administration of thalidomide (50 mg/kg)
signiﬁcantly reduced the content of hydroxyproline in lung tissue
(P = 0.034). These ﬁndings were consistent with the histological
results.
4. Discussion
The aim of the present study was to assess the effect of thalido-
mide on paraquat-induced pulmonary injury in mice. PQ, a quaterna-
ry ammonium herbicide, is a very toxic substance for humans and
animals. Intoxication with PQ causes severe lung damage in the
chronic stages in humans. Although the mechanism underlying the
development of lung injury by PQ is not obvious, previous studies
showed that oxidative and inﬂammatory mediators induced by PQ
could result in tissue inﬂammation and injury. Respiratory distress
arises as a result of alveolar epithelial cell disruption, hemorrhage, in-
ﬁltration of inﬂammatory cells into the interstitial and alveolar
spaces, edema, ﬁbroblast proliferation, collagen deposition and pro-
gressive ﬁbrosis [4]. Several cytokines, chemokines, and growth
factors have been identiﬁed to be involved in the molecular patho-
genesis of PQ poisoning. It has been shown that inﬂammatory and
proﬁbrogenic cytokines TNF-α, IL-1β, IL-6 and TGF-β1 play an impor-
tant role in PQ-induced pulmonary inﬂammatory and ﬁbrosis
[3,5,18]. PQ-induced reactive oxygen species can activate intracellular
transcription factors such as nuclear factor (NF)-κB, thereby enhanc-
ing TNF-α and IL-1β expression. TNF-α is one of the early cytokines
that are released from alveolar macrophages in the early inﬂammato-
ry and late ﬁbrotic phases of lung injury. TNF-α activates the prolifer-
ation of ﬁbroblasts, expression of cellular matrix metalloproteinases
(MMPs) and the release of other proinﬂammatory cytokines. IL-6 is
signiﬁcantly elevates in PQ-induced lung injury and promotes
ﬁbrogenesis either alone or concomitant with TNF-α [3]. Increased
production of TGF-β1 from lung injury caused by PQ has been associ-
ated with inﬂammation and ﬁbrosis of lung tissue [5,19]. TGF-β1 as
an important growth factor promotes tissue ﬁbrosis. In experimentalmodels of pulmonary ﬁbrosis, TGF-β1 has been shown to be an im-
portant ﬁbrogenic mediator which stimulates ﬁbroblast proliferation,
matrix protein production and collagen synthesis [20]. Moreover, it is
known to induce IL-6 production [10]. PQ exposure induces the
expression of nitric oxide synthase (NOS) through generation of reac-
tive oxygen species. Although, the role of NO in the pathogenesis of
PQ toxicity has been controversial, this ﬁnding suggests that NO has
a critical role in PQ-induced cytotoxicity [4,6,21]. It has also been
reported that NOS inhibitors have protective effects against PQ-
induced lung injury [22].
Thalidomide and its analogs are immunomodulatory drugs that
exhibit anti-inﬂammatory, anti-proliferative and anti-angiogenic ac-
tivities. These effects are responsible for the clinical effectiveness of
thalidomide in erythema nodosum leprosum, lupus erythematosus,
graft versus host disease, multiple myeloma, rheumatoid arthritis
and Crohn's disease [12]. In addition there are several studies that
showed thalidomide has therapeutic effects in various ﬁbrotic and in-
ﬂammatory disorders such as bleomycin-induced lung ﬁbrosis [11],
peritonitis [14], pancreatitis [23] and experimental diabetes [13].
Pulmonary ﬁbrosis is a serious consequence of PQ poisoning. We
suggested that thalidomide may be an appropriate candidate to inhibit
PQ-induced pulmonary inﬂammation and ﬁbrosis. Most recently, the
effect of thalidomide inmousemodel of PQ toxicity has been investigat-
ed by a Chinese group [24]. Our study has been done independently of
the Chinese study. In our study, thalidomide treatment reduced
PQ-induced lung injury in mice. We showed that PQ-induced
proinﬂammatory cytokines, including TNF-α, IL-1β and IL-6 in the
lungs of mice were reduced by thalidomide treatment in a dose-
dependent manner. As mentioned above, these mediators have a criti-
cal role in the progression of lung inﬂammation and ﬁbrosis by PQ. Fur-
thermore, we found that chronic thalidomide treatment had the ability
to reduce the levels of growth factor TGF-β1 in the lungs of mice.
Indeed, blocking the production of the proinﬂammatory mediators by
thalidomide decreases pulmonary inﬂammation and suppresses specif-
ic pathways that lead to alveolar epithelial cell disruption and lung
ﬁbrosis.
Our previous study showed that thalidomide has the ability to
suppress production of NO during inﬂammatory processes [13]. It is
reported that thalidomide exhibits NOS-inhibitory activity [14,25].
In our study pulmonary levels of NO in the PQ group were signiﬁcant-
ly higher than in other groups. Thalidomide administration signiﬁ-
cantly decreased the elevation of NO production in the PQ-treated
group. This reduction in the formation of NO by thalidomide may con-
tribute to the inﬂammation, lipid peroxidation and ﬁbrosis in the lung
tissues in PQ-treated animals.
In our study we found that the activity of myeloperoxidase (MPO)
was signiﬁcantly increased in lung tissue from mice that had been
treated with PQ. MPO is a peroxidase enzyme that is synthesized
and secreted by neutrophils and monocytes. MPO catalyzes the for-
mation of hypochlorous acid and other reactive molecular species
and contributes to tissue damage during oxidative stress and inﬂam-
mation [26]. Increased MPO activity represents the extensive inﬁltra-
tion of macrophages and neutrophils in the lungs of PQ exposed mice.
Our histological results conﬁrmed the inﬁltration of polymorphonu-
clear leukocytes (PMN) into the lungs. Thalidomide administration
caused a signiﬁcant reduction of the interstitial inﬂammatory cell in-
ﬁltration and MPO activity in the lung of mice exposed to PQ. In
agreement with our study it has been reported that thalidomide
was able to reduce MPO activity in various inﬂammatory condi-
tions [23,27]. This ﬁnding indicates that thalidomide reduces lipid
peroxidation and improves PQ-induced pulmonary inﬂammation.
Consistent with previous observations, our study showed that
lung hydroxyproline levels increased in PQ-treated mice, and treat-
ment with thalidomide reduced the hydroxyproline content. We
found that PQ produced an increase in pathologic score that was
decreased by thalidomide. Also, our histological analysis showed
Fig. 4. (A) Histopathological appearance of the lung sections in (a) control, (b) PQ + thalidomide (25 mg/kg/day), (c) PQ + thalidomide (50 mg/kg/day), and (d) PQ groups. Lung
injury was induced by a single dose (20 mg/kg, i.p.) of paraquat and mice were treated with thalidomide (25 and 50 mg/kg/day, i.p.). Widespread thickening of alveolar septum,
inﬁltration of inﬂammatory cells, and cellular proliferation of connective tissues were observed in PQ group. Treatment with thalidomide reduced the histological alterations
induced by PQ intoxication. The lung sections were analyzed by hematoxylin and eosin (H&E) staining (magniﬁcation is 400×). (B) Pathology score of lung was signiﬁcantly
lower in the PQ + thalidomide (50 mg/kg/day) group than in the PQ group. *P b 0.001 compared with normal group; §P b 0.05 compared with PQ group.
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ing of the alveolar septum and inﬁltration of various inﬂammatory
cells. Histological changes were attenuated by administration of tha-
lidomide in a dose dependent manner. This ﬁnding suggests that
the beneﬁcial effect of thalidomide on PQ-induced lung inﬂammation
and ﬁbrosis may be associated in part by the inhibition of neutrophil
migration into the lungs. The PQ-induced lung damage begins at anearly stage of PQ poisoning and the treatment with thalidomide
should be applied at an early time point of exposure to PQ.
In conclusion, according to the data presented in this study it
seems that thalidomide treatment has a protective effect against
PQ-induced pulmonary injury in mice through a number of distinct
mechanisms. Nevertheless, further studies are needed to support
these ﬁndings.
Fig. 5. Hydroxyproline content of lung tissue in experimental groups. PQ exposure
increased hydroxyproline levels and treatment with thalidomide (50 mg/kg/day)
inhibited the increase of lung hydroxyproline content. Data are means ± SD (two
replicates in each assay), n = 8. *P = 0.001 compared with normal group;
§P b 0.05 compared with PQ group.
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